CAR-T & Cellular Therapy
T-cell engagers in multiple myeloma: current challenges and future outlooks
Several novel agents have been approved in the field of multiple myeloma and have greatly transformed the treatment landscape of…
Date: 24th August 2022
The importance of patient-reported outcomes in CAR-T recipients
CAR-T therapies have been approved for use in several hematological malignancies, and have greatly improved treatment options for patients, especially…
Date: 17th August 2022
CAR-T therapy in myeloma and lymphoma
CAR-T therapy has revolutionized the treatment landscape of several hematological malignancies, and ongoing clinical trials continue to provide valuable data…
Date: 12th August 2022
CAR-T therapy in AML: challenges and future outlooks
Acute myeloid leukemia (AML) is an aggressive and heterogeneous hematological malignancy that poses many challenges for diagnosis and treatment. While…
Date: 10th August 2022
The current state of CAR-T therapy in lymphoma
Over the last few decades, advances in immunotherapies including CAR-T therapy have revolutionized the treatment of patients with relapsed/refractory (R/R)…
Date: 5th August 2022
Myeloma treatment updates from EHA 2022
While multiple myeloma remains a challenging disease to treat, there have been several advances in the field over the years….
Date: 3rd August 2022
The future of CAR-T therapy in ALL
Acute lymphoblastic leukemia (ALL) is an aggressive and heterogeneous disease with a high mortality rate. However, several advances have been…
Date: 20th July 2022
An insight into novel targets in myeloma and mechanisms of resistance to PIs and IMiDs
Multiple myeloma has seen many advances in recent years, and novel targeted agents are transforming the field. Several immunotherapies, including…
Date: 15th July 2022
Harnessing the power of immunotherapy in myeloma and amyloidosis
The myeloma treatment landscape has seen a lot of progress in the last few years, with several novel therapies emerging,…
Date: 20th May 2022
Genomics in the age of immuno-oncology
Immunotherapies are at the forefront of myeloma treatment and there are many questions remaining. Defining high-risk is important when making…
Date: 29th April 2022
ASH 2021: a deep dive into ALL immunotherapy
Various forms of immunotherapy represent a novel treatment option, especially for patients who progress from conventional chemotherapy hematopoietic stem-cell transplantation…
Date: 25th March 2022
ASH 2021: what did ASH 2021 mean for MDS?
With high rates of relapse in patients with myelodysplastic syndromes (MDS), there is a great unmet need for novel treatments…
Date: 18th March 2022
